Versions Compared

Version Old Version 25 New Version Current
Changes made by

Nicola Newton

Nicola Newton

Saved on

Key

  • This line was added.
  • This line was removed.
  • Formatting was changed.

Image RemovedImage Added


Project Scope 

Clarify

The Project has successfully completed the first step of clarifying the definitions and labels

.
  • Experience sharing of methodologies used to set thresholds for QTL parameters with a clear link to the scientific question of the clinical trial.
    • Develop a guidance for threshold-setting methodologies for QTL parameters with a clear link to the scientific question of the clinical trial.

    linked to QTL monitoring. Recommendations on how to derive thresholds for QTL monitoring have been developed.  

    The next stage shall be to: 

    • Share this acquired knowledge and common understanding within the industry. 
    • Continue the discussion on further refining the (statistical) methodology regarding threshold derivation for QTL monitoring. 

    Closely follow ICH (R3) developments regarding risk-based monitoring and discuss/evaluate whether this has impacts on the guidance provided so far (QTL vs. acceptable range). 



    Lauren White ( Coordinator) lauren@phuse 
    Project LeadsEmail
    Nathalie van Borrendam (Janssen Research & Development) , Johnson & Johnsonnvanborr@its.jnj.com
    Annett Keller (, Boehringer Ingelheim) Ingelheim annett.keller@boehringer-ingelheim.com
    Alex Pearce, PHUSE Project Assistant 

    alexandra@phuse.global


    Status
    colourBlue
    titleCurrent Status
    Q4 2024

    • Establish draft paper.



    Objectives & DeliverablesTimelines
    Challenges in QTL threshold setting – Experience sharing and high-level recommendations for the industryQ3 2022

    Guidance document on QTL threshold-setting methodologies

    		Q1
    2023
    Status
    colourBlue
    titleCurrent Status
    Q2
    2023

    Finalisation of guidance document on QTL- Threshold setting methodologies is being reviewed

    Project MembersOrganisationsAnnett KellerBoehringer IngelheimArseny KhaplanovParexelDaniel Kowalski ClinscienceDebra JendrasekDaiichi SankyoJim WangJanssen Research & DevelopmentMarcus EeMaithy MuliMerckMarion WolfsJanssen Research & DevelopmentMarta KozińskaAstrazenecaNathalie van BorrendamJanssen Research & DevelopmentPatrice BennerMerckStefano SainoMerckSteve YoungCluePointsSteven Andrew GilbertPfizerSusan TalbotAmgenYu Meng Merck